Improving long-term outcomes of coronary intervention in patients with diabetes

Chinese Medical Journal

Volumn 122, Issue 6, 2009, Pages 605-607

  Shen, Wei Feng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; INSULIN; PACLITAXEL; RAPAMYCIN; SULFONYLUREA;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DIABETIC PATIENT; DRUG ELUTING STENT; EDITORIAL; GLYCEMIC CONTROL; HUMAN; IN-STENT RESTENOSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RISK ASSESSMENT; RISK REDUCTION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; METHODOLOGY; NOTE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; DIABETES COMPLICATIONS; DRUG-ELUTING STENTS; HUMANS; TREATMENT OUTCOME;

EID: 67649807531     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.06.001     Document Type: Editorial

References (27)

1. Hu DY, Pan CY, Yu JM for the China Heart Survey Group. The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey. Eur Heart J 2006; 27: 2573-2579.
2. Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk. A population study of 3.3 million people. Circulation 2008; 117: 1945-1954.
3. Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury T, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2004; 109: 476-480.
4. Yang YJ, Xu B, Kang S, Pei WD, Chen JL, Qiao SB, et al. Comparison of in-hospital and long-term outcomes between a Cypher stent and a Taxus stent in Chinese diabetic patients with coronary artery disease. Chin Med J 2007; 120: 1868-1873.
5. Dou KF, Xu B, Yang YJ, Chen JL, Qiao SB, Li JJ, et al. Two-year clinical outcome after successful implantation of drug-eluting and bare-metal stents in diabetic patients: results from a real-world single center registry. Chin Med J 2009; 122: 613-617.
6. Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004; 109: 2273-2278.
7. Jimenez-Quevedo P, Sabate M, Angiolillo DJ, Alfonso F, Hernandez-Antolin R, SanMartin M, et al. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenosis: long-term results of the DIABETES trial. Eur Heart J 2007; 28: 1946-1952.
8. Ortolani P, Balducelli M, Marzaroli P, Piovaccari G, Menozzi A, Guiducci V, et al. Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions. Results from a real-world multicenter registry. Circulation 2008; 117: 923-930.
9. Daemen J, Kuck KH, Macaya C, LeGrand V, Vrolix M, Carrie D, et al. Multivessel coronary revascularization in patients with and without diabetes mellitus. J Am Coll Cardiol 2008; 52: 1957-1967.
10. Kirtane AJ, Ellis SG, Dawkins KD, Colombo A, Grube E, Popma JJ, et al. Paclitaxel-eluting coronary stents in patients with diabetes mellitus. J Am Coll Cardiol 2008; 51: 708-715.
11. Billinger M, Beutler J, Taghetchian KR, Remondino A, Wenaweser P, Cook S, et al. Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients. Eur Heart J 2008; 29: 718-725.
12. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus. J Am Coll Cardiol 2008; 52: 727-733.
13. Mahmud E, Bromberg-Marin G, Palakodeti V, Ang L, Creanga D, Demaria AN. Clinical efficacy of drug-eluting stents in diabetic patients. J Am Coll Cardiol 2008; 51: 2385-2395.
14. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663-670.
15. Abizaid A, Costa MA, Blanchard D, Albertal M, Eltchanioff H, Guagliumi G, et al for the Ravel Investigators. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL trial. Eur Heart J 2004; 25: 107-112.
16. Kimura M, Mintz GS, Weissman NJ, Dawkins KD, Grube E, Ellis SG, et al. Meta-analysis of the effects of paclitaxel-eluting stents versus bare metal stents on volumetric intravascular ultrasound in patients with versus without diabetes mellitus. Am J Cardiol 2008; 101: 1263-1268.
17. Jensen LO, Maeng M, Thayssen P, Christiansen EH, Hansen KN, Galloe A, et al. Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: The Randomized Diabetes and Drug-Eluting Stent (DiabeDES) intravascular ultrasound trial. Eur Heart J 2009; 29: 2733-2741.
18. Iijima R, Ndrepepa G, Mehilli J, Markwardt C, Bruskina O, Pache J, et al. Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. Am Heart J 2007; 154: 688-693.
19. Fleg JL, Mete M, Howard BV, Umans JG, Roman MJ, Ratner RE, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes. J Am Coll Cardiol 2008; 2198-2205.
20. Michos ED, Ardehali R, Blumenthal RA, Ardehali H. Aspirin and clopidogrel resistance. Mayo Clin Proc 2006; 81: 518-526.
21. Brar SS, Kim J, Brar SK, Zadegan R, Ree M, Liu IL, et al. Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. J Am Coll Cardiol 2008; 51: 2220-2227.
22. Holman RR, Paul SK, Bethel A, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359: 1565-1576.
23. Pu L, Lu L, Shen WF, Zhang Q, Zhang RY, Zhang JS, et al. Increased serum glycated albumin level is associated with the presence and severity of coronary artery disease in type 2 diabetic patients. Circ J 2007; 71: 1067-1073.
24. Lu L, Pu LJ, Chen QJ, Wang L, Peng W, Yan X, et al. Increased glycated albumin and decreased esRAGE concentrations are associated with in-stent restenosis in Chinese diabetic patients. Chem Clin Acta 2008; 396: 33-37.
25. Langenfeld MR, Forst T, Hohberg C, Kann P, Lubben G, Konrad T, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetic mellitus: results from a controlled randomized study. Circulation 2005; 111: 2525-2531.
26. Dormandy JA, Charbonner B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macrovascular Events): a randomized controlled trial. Lancet 2005; 366: 1279-1289.
27. Nakayama T, Komiyama N, Yokoyama M, Namikawa S, Kuroda N, Kobayashi Y, et al. Pioglitazone induced regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound. Int J Cardiol 2008; Epub ahead of print.